Ryzodeg 70/30 FDA Approval History
Last updated by Judith Stewart, BPharm on May 4, 2020.
FDA Approved: Yes (Discontinued) (First approved September 25, 2015)
Brand name: Ryzodeg 70/30
Generic name: insulin degludec and insulin aspart
Dosage form: Injection
Company: Novo Nordisk
Treatment for: Diabetes, Type 1, Type 2 Diabetes
Ryzodeg 70/30 (insulin degludec and insulin aspart) is a long-acting insulin analog and rapid-acting human insulin analog combination indicated to improve glycemic control in adults with diabetes mellitus.
Development timeline for Ryzodeg 70/30
| Date | Article |
|---|---|
| Sep 25, 2015 | Approval FDA Approves Ryzodeg 70/30 (insulin degludec/insulin aspart) for Diabetes Mellitus |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.